Amanda Gillespie-Twardy

Statistics

Publications

Citations

698

H-Index

Active since

2015

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Chinese Academy of Medical Sciences & Peking Union Medical College

Fred Hutch Cancer Center

University of Cologne

University of California, Irvine

Amanda Gillespie-Twardy is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and chronic lymphocytic leukemia therapy.

Publications per year

2015–2024

Publications

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen et al. · New England Journal of Medicine · 2022 · 457 citations · Full text

Medicine, Oncology, Pharmacology +16

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +15

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna et al. · Blood · 2024 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna et al. · Blood · 2023 · 24 citations

Medicine, Oncology, Pharmacology +13

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma

Christine G. Roth, Amanda Gillespie-Twardy, Stanley M. Marks et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2016 · 22 citations · Full text

Medicine, Hematology, Oncology +17

1–5 of 8